NasdaqCM - Nasdaq Real Time Price USD

Lucid Diagnostics Inc. (LUCD)

1.2600
+0.0300
+(2.44%)
At close: May 16 at 4:00:02 PM EDT
1.2400
-0.02
(-1.59%)
After hours: May 16 at 7:00:48 PM EDT
Loading Chart for LUCD
  • Previous Close 1.2300
  • Open 1.2400
  • Bid 1.2200 x 700
  • Ask --
  • Day's Range 1.2200 - 1.2900
  • 52 Week Range 0.6810 - 1.8000
  • Volume 813,091
  • Avg. Volume 1,073,345
  • Market Cap (intraday) 132.783M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0500
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.75

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

www.luciddx.com

72

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LUCD

View More

Performance Overview: LUCD

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LUCD
53.85%
S&P 500 (^GSPC)
1.30%

1-Year Return

LUCD
41.57%
S&P 500 (^GSPC)
12.48%

3-Year Return

LUCD
39.13%
S&P 500 (^GSPC)
48.66%

5-Year Return

LUCD
90.12%
S&P 500 (^GSPC)
108.07%

Compare To: LUCD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LUCD

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    132.78M

  • Enterprise Value

    186.10M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.65

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    42.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -92.04%

  • Return on Equity (ttm)

    -1,897.34%

  • Revenue (ttm)

    4.17M

  • Net Income Avi to Common (ttm)

    -70.94M

  • Diluted EPS (ttm)

    -1.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    25.24M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -29.43M

Research Analysis: LUCD

View More

Company Insights: LUCD

Research Reports: LUCD

View More

People Also Watch